TickerFacts.

Company research / TMCI

Treace Medical Concepts, Inc. (TMCI)

Build a valuation ↗↓ Download CSV

SEC name TREACE MEDICAL CONCEPTS, INC. · CIK 0001630627 · Nasdaq · Surgical & Medical Instruments & Apparatus

  • Sector Manufacturing
  • Incorporated FL
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Treace Medical Concepts, Inc. reported revenue of $212.69M. Revenue grew 1.6% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $205.31M.

Key ratios (year ended 2025-12-31)

79.8%
Gross margin
-25.5%
Operating margin
-27.7%
Net margin
-67.6%
Return on year-end equity
1.6%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-02

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$205.31M$212.69M$209.36M$187.12M$141.84M$94.42M$57.37M$39.42M
Cost of Revenue$42.19M$42.94M$41.09M$35.18M$25.53M$16.89M$12.47M$7.63M
Gross Profit$163.12M$169.75M$168.26M$151.94M$116.31M$77.53M$44.90M$31.79M
R&D Expense$18.22M$20.28M$20.59M$15.44M$13.58M$10.20M$5.85M$5.07M
Operating Income-$53.72M-$54.15M-$55.69M-$51.43M-$34.84M-$16.51M$855.0K-$3.54M
Depreciation & Amortization$8.37M$10.62M$8.42M$5.35M$2.13M$685.0K$1.21M$793.0K
EBITDA-$45.35M-$43.53M-$47.27M-$46.08M-$32.71M-$15.82M$2.06M-$2.74M
Net Income-$59.52M-$59.00M-$55.74M-$49.53M-$42.81M-$20.55M-$3.67M-$4.26M
EPS (Diluted)n/a-$0.93-$0.90-$0.81-$0.77-$0.43-$0.12n/a
Total Assets$181.06M$190.58M$217.09M$251.91M$159.02M$140.82M$41.81Mn/a
Total Liabilities$113.32M$103.25M$104.20M$113.97M$98.50M$47.75M$41.03Mn/a
Long-Term Debt$56.04M$55.58M$53.31M$53.01M$52.71M$29.36M$30.98Mn/a
Shareholders' Equity$67.74M$87.33M$112.89M$137.94M$60.53M$93.07M$776.0K$3.16M
Cash & Equivalents$12.61M$10.71M$11.35M$12.98M$19.47M$105.83M$18.08M$12.14M
Operating Cash Flow-$14.58M-$15.97M-$37.17M-$34.58M-$30.65M-$17.19M-$4.49M-$7.67M
Capital Expenditures$10.47M$13.52M$11.59M$11.46M$14.84M$2.71M$1.07M$1.21M
Free Cash Flow-$25.05M-$29.49M-$48.76M-$46.03M-$45.49M-$19.90M-$5.56M-$8.88M
Shares Outstandingn/an/an/a61.75M55.63M54.18Mn/an/a
Weighted Average Diluted Sharesn/a63.27M62.11M60.85M55.28M48.42M37.07Mn/a
EPS (Basic)n/a-$0.93-$0.90-$0.81-$0.77-$0.43-$0.12n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView